Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Vincristine 6Doxorubicin 5Cyclophosphamide 5merphos 4Specimen Handling 4Radiotherapy 4Prednisone 4Methotrexate 4pegaspargase 3calaspargase pegol 3Prednisolone 3Methylprednisolone 3Hydrocortisone 3Etoposide 3Daunorubicin 3Cytarabine 3Biopsy 3Asparaginase 3exifone 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Thioguanine 2Spinal Puncture 2Mercaptopurine 2Medrol Veriderm 2Magnetic Resonance Spectroscopy 2Filgrastim 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Hyaluronoglucosaminidase × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡